At a media event at Novo Nordisk (NOV: N) headquarters in Copenhagen, the Danish diabetes giant provided insights into its clinical and commercial strategies on Wednesday.
While chief executive Lars Fruergaard Jørgensen said the firm was “more and more becoming a GLP-1 based company," chief scientific officer Mads Krogsgaard Thomsen said Novo was “maybe 8-10 years ahead of competition in oral GLP-1.”
The firm has suffered from declining sales in parts of its key revenue-generating insulin portfolio recently, but has a promising story to tell about the potential for new forms of diabetes management, including the first oral biologic, as well as the potential to play in the growing market for obesity therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze